CU24410B1 - Benzimidazol-2-aminas como inhibidores de midh1 - Google Patents

Benzimidazol-2-aminas como inhibidores de midh1

Info

Publication number
CU24410B1
CU24410B1 CU2016000120A CU20160120A CU24410B1 CU 24410 B1 CU24410 B1 CU 24410B1 CU 2016000120 A CU2016000120 A CU 2016000120A CU 20160120 A CU20160120 A CU 20160120A CU 24410 B1 CU24410 B1 CU 24410B1
Authority
CU
Cuba
Prior art keywords
sup
benzimidazol
aminas
midh1
formula
Prior art date
Application number
CU2016000120A
Other languages
English (en)
Other versions
CU20160120A7 (es
Inventor
Sonja Anlauf
Marcus Bauser
Paul Matthew Blaney
Stefan Kaulfuss
Roland Neuhaus
Duy Nguyen
Olaf Panknin
Hartmut Rehwinkel
Sven Ring
Wolfgang Schwede
Holger Siebeneicher
Katja Zimmermann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24410(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20160120A7 publication Critical patent/CU20160120A7/es
Publication of CU24410B1 publication Critical patent/CU24410B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a benzimidazol-2-aminas con la fórmula general (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>que inhiben a la isocitrato deshidrogenasa 1 mutada (mIDH1 R132H), donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11 </sup>y R<sup>12 </sup>son según se los define aquí, métodos para elaborarlos y compuestos intermediarios útiles en su elaboración. Los compuestos de fórmula I son útiles en la profilaxis o el tratamiento de diversas enfermedades, particularmente de los neoplasmas.</p>
CU2016000120A 2014-02-11 2015-02-10 Benzimidazol-2-aminas como inhibidores de midh1 CU24410B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14154680 2014-02-11
EP14182002 2014-08-22
PCT/EP2015/052676 WO2015121210A1 (en) 2014-02-11 2015-02-10 Benzimidazol-2-amines as midh1 inhibitors

Publications (2)

Publication Number Publication Date
CU20160120A7 CU20160120A7 (es) 2016-12-23
CU24410B1 true CU24410B1 (es) 2019-05-03

Family

ID=52462928

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000120A CU24410B1 (es) 2014-02-11 2015-02-10 Benzimidazol-2-aminas como inhibidores de midh1

Country Status (23)

Country Link
US (2) US9957235B2 (es)
EP (1) EP3105209B1 (es)
JP (1) JP6534675B2 (es)
KR (1) KR20160115991A (es)
CN (1) CN106573897B (es)
AP (1) AP2016009371A0 (es)
AU (1) AU2015217788B2 (es)
BR (1) BR112016018604A2 (es)
CA (1) CA2939026A1 (es)
CL (1) CL2016002033A1 (es)
CR (1) CR20160361A (es)
CU (1) CU24410B1 (es)
DO (1) DOP2016000208A (es)
EA (1) EA031655B1 (es)
IL (1) IL246785A0 (es)
MX (1) MX2016010474A (es)
PE (1) PE20170143A1 (es)
PH (1) PH12016501581A1 (es)
SG (1) SG11201605810WA (es)
SV (1) SV2016005257A (es)
TW (1) TWI666202B (es)
UY (1) UY35991A (es)
WO (1) WO2015121210A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
ES2732902T3 (es) 2014-02-11 2019-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Bencimidazol-2-aminas como inhibidores de MIDH1
JP6648116B2 (ja) 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
ES2953347T3 (es) 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
WO2016062677A1 (en) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2965213A1 (en) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
EP3303302B1 (en) * 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
WO2017005674A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
JP6824954B2 (ja) * 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
EP3121166A1 (en) * 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201708193A (zh) * 2015-07-27 2017-03-01 拜耳製藥公司 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑
TW201718513A (zh) * 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
AU2017217536A1 (en) * 2016-02-09 2018-08-09 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (IDO)
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
JP2020535112A (ja) * 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
PT3720442T (pt) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
JP7258059B2 (ja) * 2018-06-26 2023-04-14 昆薬集団股▲フン▼有限公司 ベンズイミダゾール誘導体及びそのｉｄｈ１阻害剤としての応用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
IL299859A (en) 2020-07-21 2023-03-01 Daiichi Sankyo Co Ltd A combination drug of temozolomide and a mutant IDH1 enzyme inhibitor
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
CN1161340C (zh) 1998-11-30 2004-08-11 先灵公司 为玻连蛋白受体拮抗剂的苯并咪唑化合物
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
MXPA04008458A (es) 2002-03-01 2004-12-06 Smithkline Beecham Corp Diamino pirimidinas y su uso como inhibidores de angiogenesis.
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
JP4842829B2 (ja) 2003-10-31 2011-12-21 武田薬品工業株式会社 含窒素縮合複素環化合物
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
WO2006038738A1 (ja) 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
US7893267B2 (en) 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
WO2009116074A2 (en) 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
EP2445345B1 (en) * 2009-06-23 2014-08-27 The Translational Genomics Research Institute Benzamide derivatives
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103435554A (zh) * 2013-09-06 2013-12-11 中国药科大学 2-苯氨基苯并咪唑类化合物及其用途
ES2732902T3 (es) 2014-02-11 2019-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Bencimidazol-2-aminas como inhibidores de MIDH1
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
WO2016062677A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2965213A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
EP3297437A4 (en) 2015-05-18 2019-02-27 Translational Drug Development Llc HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KINASES
JP7028765B2 (ja) 2015-05-22 2022-03-02 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー ベンズアミドおよび活性化合物組成物および使用方法
EP3303302B1 (en) 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
WO2017005674A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
JP6824954B2 (ja) 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
TW201708193A (zh) 2015-07-27 2017-03-01 拜耳製藥公司 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑
JP6768078B2 (ja) 2016-03-02 2020-10-14 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
CL2016002033A1 (es) 2017-03-31
AU2015217788A1 (en) 2016-08-04
CR20160361A (es) 2016-10-03
MX2016010474A (es) 2016-10-31
UY35991A (es) 2015-09-30
PE20170143A1 (es) 2017-03-19
EA201691590A1 (ru) 2017-02-28
SV2016005257A (es) 2018-10-02
EP3105209B1 (en) 2019-08-21
EP3105209A1 (en) 2016-12-21
WO2015121210A1 (en) 2015-08-20
BR112016018604A2 (pt) 2017-08-08
KR20160115991A (ko) 2016-10-06
CA2939026A1 (en) 2015-08-20
US10442772B2 (en) 2019-10-15
CN106573897A (zh) 2017-04-19
DOP2016000208A (es) 2016-09-15
AU2015217788B2 (en) 2019-06-27
JP2017505790A (ja) 2017-02-23
PH12016501581A1 (en) 2017-02-06
IL246785A0 (en) 2016-08-31
TW201613874A (en) 2016-04-16
CU20160120A7 (es) 2016-12-23
JP6534675B2 (ja) 2019-06-26
CN106573897B (zh) 2019-09-24
AP2016009371A0 (en) 2016-08-31
TWI666202B (zh) 2019-07-21
EA031655B1 (ru) 2019-02-28
US20190062285A1 (en) 2019-02-28
SG11201605810WA (en) 2016-08-30
US20170197921A1 (en) 2017-07-13
US9957235B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2017008444A (es) Picolinamidas como fungicidas.
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
MA40076A (fr) Inhibiteurs de syk
DOP2017000278A (es) Piridinas sustituidas y método de uso
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
EA201690844A1 (ru) Ингибиторы gsk-3
DOP2016000120A (es) Nuevos inhibidores de dgat2
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos